Skip to content
Search

Latest Stories

Delay in relaxing Covid restrictions hit Asos sales

DELAY in the easing of Covid-19 restrictions and harsh summer weather led to a slowdown in sales at Asos last month, The Times reported.

The online retailer registered a 27 per cent increase in the group’s revenue to £1.29 billion in the four months to June 30, backed by surge in sales.


The business hailed it as “strong, against a backdrop of continued restrictions on consumers, volatile demand and increased global supply chain pressures”.

Asos, which is focused on young shoppers, said that sales in the past three weeks were muted as young people’s hopes of going out in groups on June 21 dashed following the delay in lifting restrictions.

This resulted in reduced sale of going-out dresses.

Besides, the rainy summer in the UK dampened demand for summer outfits.

In the wake of global uncertainty due to the pandemic, the company expected growth in the fourth quarter to be comparable with last year and full-year adjusted pre-tax profits to be in line with expectations.

This adjustment would strip out £6 million of interest charges related to its £500m bond issue in April and costs associated with its recent £295m Topshop acquisitions.

Asos disclosed underlying sales figures for the last quarter, which showed a slower rate of growth than its reported figures as its level of customer returns was lower than it estimated.

As a result, its fourth-quarter sales in 2020 were higher at £1.1bn than the £1.01bn that it reported last year. Its underlying growth during this quarter was 17 per cent, or 21 per cent at constant currency, rather than the 27 per cent reported growth.

Founded in 2000 by Nick Robertson, Asos is currently valued at £4.68bn, but is still listed on London’s junior Aim market.

“Although mindful of the continued impacts of the pandemic on our customers in the short term, we believe that the structure of the global ecommerce fashion market has changed for ever, which will drive an increase in online fashion sales over the long term,” said Nick Beighton, Asos chief executive.

“We’re excited about the size of the prize ahead of us and the opportunity of delivering on our ambition of being the number one destination for fashion-loving twentysomethings,” he said.

Earlier this week, the company announced to sell Topshop and selected Asos ranges in Nordstrom shops in the US.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less